A Phase I Study of the Hsp90 Inhibitor AUY922 Plus Capecitabine for the Treatment of Patients With Advanced Solid Tumors

NCT01226732 Phase 1 COMPLETED Results posted

The investigators propose this Phase I trial of the combination of AUY922 and capecitabine to determine the maximum tolerated dose (MTD) in patients with advanced solid tumors. This combination treatment has potential applicability in tumor types where capecitabine or fluorouracil is a treatment option, including colorectal and breast cancer.

Details

Lead sponsor	SCRI Development Innovations, LLC
Phase	Phase 1
Status	COMPLETED
Enrolment	23
Start date	2010-11
Completion	2014-06

Conditions

• Metastatic or Unresectable Solid Tumor Malignancy

Interventions

• Capecitabine
• Hsp90 Inhibitor AUY 922

Primary outcomes

• Dose Determination — 18 months
  To determine the maximum tolerated dose (MTD) of AUY922 plus capecitabine in patients with advanced solid tumors.

Countries

United States